An interventional study of Dexmedetomidine in Chronic Migraine, sponsored by Beni-Suef University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Beni-Suef University · Not applicable, Interventional, and Treatment
Among 29 studies in Migraine Disorders with a site in Egypt — 17 open to participants now, 18 under way, 2 of them phase 3. Migraine Disorders · Egypt.
Among the 29 studies in Migraine Disorders with a site in Egypt, this one is the 9th largest by planned enrollment of the 23 interventional ones, is one of 4 that started in 2026, is one of 13 with no phase, reaches primary completion later than 17 of the 17 other live ones, and was the 28th registered.
1,657 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
This study's planned enrollment of 146 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Browse Migraine Disorders studies →17 of the 29 studies in Migraine Disorders with a site in Egypt are open now, in 1 country. Each count lists the studies.
Of the 216 Migraine Disorders studies recruiting now, 65 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →29 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 4 started in 2026.
Median enrollment 90 across the 23 interventional studies, 103 across the 6 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
None of the 29 has an industry lead sponsor. The 10 most frequent:
Beni-Suef University is the lead sponsor of 349 studies on the registry; 125 are open to participants now.
Beni-Suef University has 4 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Migraine Disorders with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07849283Sohag UniversityEfficacy of Cognitive Behavioral Therapy at Vestibular Migraine | 2027-02 |
| NCT07762690Beni-Suef UniversityMechanism-Based Cervical Rehabilitation for Chronic Migraine | 2027-02-25 |
| NCT07769255Beni-Suef UniversityEffect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine | 2027-03-01 |
Among the 29 studies in Migraine Disorders with a site in Egypt, from their registry updates:
Migraine is a debilitating neurological disorder characterized by recurrent headaches episodes, often accompanied by amplified perception of multiple sensory inputs such as cutaneous allodynia, photophobia, and phonophobia. The suggested mechanism in migraine is likely through sensitized trigeminovascular and dysfunctional pain modulatory systems.
Dexmedetomidine, a selective α2-adrenergic receptor agonist, exerts central antinociceptive effects by reducing neuronal hyperexcitability, glial activation, and CGRP expression. Nebulized administration provides a non-invasive alternative to intravenous use, with rapid CNS absorption and minimal sedation .
Chronic migraine: This is defined as a headache that occurs on 15 or more days in a month for more than 3 months, with migraine features present on at least 8 or more days in a month. Episodic syndromes that may be associated with migraine include recurrent gastrointestinal disturbances, involving recurrent attacks of abdominal pain, discomfort, nausea, and vomiting that may be associated with migraines; benign paroxysmal vertigo involving brief, recurrent attacks of vertigo, or benign paroxysmal torticollis is characterized by recurrent episodes of head tilt to one side.
Migraine chronification is strongly associated with central sensitization of the trigeminovascular system, a process mediated by the upregulation of calcitonin gene-related peptide (CGRP) and enhanced excitability of both brainstem and cortical pain-processing structures. Elevated CGRP plays a pivotal role in migraine pathophysiology by promoting vasodilation, neurogenic inflammation, and nociceptive facilitation.
Calcitonin gene-related peptide is a 37-amino acid neuropeptide and a potent vasodilator produced by neurons in both the central and peripheral nervous systems. Activation of CGRP-R in the trigeminovascular system plays a critical role in peripheral and central events that ultimately lead to the experience of migraine pain .
Following nerve stimulation, CGRP is released from its storage vesicles through the process of calcium-dependent exocytosis.This peripheral release of CGRP from trigeminal nerve endings is thought to trigger multiple responses induced by CGRP-R binding, which eventually lead to the sensitization of nociceptor trigeminal neurons.
The stimulation of peripheral nociceptive trigeminal neurons is hypothesized to relay the migraine pain signal through the brainstem into the brain, ultimately leading to the experience of migraine pain.
Central effects of CGRP may involve pain transmission through sensitization and activation of central processes (eg, feedback from a sensitized brain).
Objective neurophysiological biomarkers such as the nociceptive blink reflex (nBR) and trigeminal somatosensory evoked potentials (TSSEP) allow non-invasive assessment of central sensitisation through analysis of brainstem and cortical excitability. Impaired habituation in nBR and latency shifts in TSSEP have been consistently observed in migraineurs, particularly in those with chronic features.
The nociceptive blink reflex is a trigeminofacial brain-stem reflex which is used in pain research to evaluate the modulation of pain processing. Lack of habituation is a reproducible abnormality found in migraine between attacks, and attains to a model of behavior and a learning process that seem to predispose to attack occurrence. There is strong evidence that lack of habituation during stimulus repetition, despite an initial normal or low response amplitude, is a functional, probably genetically determined, hallmark of the migrainous brain between attacks.
In addition, incapacity to progressively reduce pain-related responses under repetitive stimulation. may favor mechanisms of central sensitization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
About 73 cases suffering from Chronic Migraine will undergo Nebulized dexmedetomidine (1 mcg/kg in 4 mL normal saline) Administered via jet nebulizer for 3 sessions per week for 2weeks
Drug: Dexmedetomidine
About 73 cases suffering from Chronic Migraine will undergo Nebulized 4 mL normal saline Administered via jet nebulizer for 3 sessions per week for 2weeks
Drug: Dexmedetomidine
Assessment the effect of nebulized dexmedetomidine on central Sensitization and Chronification in patients with episodic or early chronic migraine by using CGRP serum levels and trigeminal neurophysiological biomarkers (nociceptive blink reflex (nBR) and trigeminal somatosensory evoked potentials (TSSEP)).
Also known as: CGRP serum levels and trigeminal neurophysiological biomarkers
Treatment of Chronic Migraine
Assessment of the patients whom suffering from Chronic Migraine treated by Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine
Time frame: 6 Months
Start is estimated for Sep 2026; primary completion for Mar 2027, 6 months later.
Of 309 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 6 months is below that.
Counting every sponsor, half of 358 studies reached it within 15 months; a quarter within 7 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine